Randomized, Multicenter, Open-Label Trial of Autologous Cytokine-Induced Killer Cell Immunotherapy Plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer

2020 ◽  
Author(s):  
Liang Liu ◽  
Quanli Gao ◽  
Jingting Jiang ◽  
Junping Zhang ◽  
Xin Song ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Killer Cell ◽  
Small Cell ◽  
Small Cell Lung ◽  
Open Label ◽  
Cell Immunotherapy ◽  
Open Label Trial

Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial

2016 ◽  
Vol 74 (6) ◽  
pp. 1077-1085 ◽  
Author(s):  
Gaël Deplanque ◽  
Radj Gervais ◽  
Alain Vergnenegre ◽  
Lionel Falchero ◽  
Pierre-Jean Souquet ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Open Label ◽  
Open Label Trial ◽  
Line Chemotherapy

Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients

Lung Cancer ◽  
2015 ◽  
Vol 88 (3) ◽  
pp. 282-288 ◽  
Author(s):  
Oscar Arrieta ◽  
María Teresa Vega-González ◽  
Diego López-Macías ◽  
Jorge Negueb Martínez-Hernández ◽  
Ludwing Bacon-Fonseca ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Preventive Effect ◽  
Small Cell Lung ◽  
Open Label ◽  
Lung Cancer Patients ◽  
Open Label Trial

scholarly journals Efficacy and safety of endostatin in combination with chemotherapy in small cell lung cancer: a phase 2 single-arm multicenter open-label trial

2021 ◽  
Vol 10 (3) ◽  
pp. 3277-3285
Author(s):  
Yi Zhao ◽  
Xu Zhang ◽  
Chenxing Jin ◽  
Xiaomin Yu ◽  
Min Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase 2 ◽  
Efficacy And Safety ◽  
Small Cell Lung ◽  
Open Label ◽  
Open Label Trial

Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial

2011 ◽  
Vol 137 (9) ◽  
pp. 1337-1342 ◽  
Author(s):  
Charles Butts ◽  
Andrew Maksymiuk ◽  
Glenwood Goss ◽  
Denis Soulières ◽  
Ernie Marshall ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Survival Analysis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage Iiib ◽  
Small Cell Lung ◽  
Open Label ◽  
Open Label Trial
Sign in / Sign up

Export Citation Format

Share Document